AI assistant
ANAVEX LIFE SCIENCES CORP. — Director's Dealing 2025
Jun 9, 2025
32464_dirs_2025-06-09_63e2ba33-5252-421b-a2bc-0905a7d2cc26.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ANAVEX LIFE SCIENCES CORP. (AVXL)
CIK: 0001314052
Period of Report: 2025-06-05
Reporting Person: Thomas Steffen (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-06-05 | Common stock | M | 50000 | $1.76 | Acquired | 55000 | Direct |
| 2025-06-05 | Common stock | F | 11349 | $7.75 | Disposed | 43651 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-06-05 | Stock Option (Right to Buy) | $1.76 | M | 50000 | Disposed | 2025-06-15 | Common Stock (50000) | Direct |
Footnotes
F1: Represents a "net exercise" of outstanding stock options, which options were scheduled to expire on June 15, 2025. The reporting person received 38,651 shares of common stock on net exercise of an option to purchase 50,000 shares of common stock. The Company withheld 11,349 shares of common stock underlying the option as consideration for the exercise price, using the average of the high and low sales price on June 5, 2025 of $7.75, pursuant to the terms of the Company's 2007 Stock Option Plan.
F2: The options vested in three equal annual installments beginning on June 15, 2016